238 related articles for article (PubMed ID: 15758711)
1. A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database.
Mariappan P; Smith G
J Urol; 2005 Apr; 173(4):1108-11. PubMed ID: 15758711
[TBL] [Abstract][Full Text] [Related]
2. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
Yang TB; Zeng FH; Sun ZQ
Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
[TBL] [Abstract][Full Text] [Related]
4. Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup.
Sanderson KM; Cai J; Miranda G; Skinner DG; Stein JP
J Urol; 2007 Jun; 177(6):2088-94. PubMed ID: 17509294
[TBL] [Abstract][Full Text] [Related]
5. Management of low grade papillary bladder tumors.
Herr HW; Donat SM; Reuter VE
J Urol; 2007 Oct; 178(4 Pt 1):1201-5; discussion 1205. PubMed ID: 17698090
[TBL] [Abstract][Full Text] [Related]
6. Ta T1 low and intermediate transitional cell carcinoma of the bladder: recurrence rates and the timing of check cystoscopies within the first year.
Guney S; Guney N; Canogullari Z; Ergenekon E
Urol Int; 2008; 80(2):124-8. PubMed ID: 18362479
[TBL] [Abstract][Full Text] [Related]
7. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
Raman JD; Sosa RE; Vaughan ED; Scherr DS
Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
[TBL] [Abstract][Full Text] [Related]
8. Pattern of recurrence changes in noninvasive bladder tumors observed during 2 decades.
Mariappan P; Smith G; Lamb AD; Grigor KM; Tolley DA
J Urol; 2007 Mar; 177(3):867-75; discussion 875. PubMed ID: 17296362
[TBL] [Abstract][Full Text] [Related]
9. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
[TBL] [Abstract][Full Text] [Related]
10. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years.
Holmäng S; Hedelin H; Anderström C; Johansson SL
J Urol; 1995 Jun; 153(6):1823-6; discussion 1826-7. PubMed ID: 7752327
[TBL] [Abstract][Full Text] [Related]
11. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer.
Boudreaux KJ; Clark PE; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Chang SS
J Urol; 2009 Feb; 181(2):540-5; discussion 546. PubMed ID: 19084855
[TBL] [Abstract][Full Text] [Related]
12. Does the management of bladder perforation during transurethral resection of superficial bladder tumors predispose to extravesical tumor recurrence?
Skolarikos A; Chrisofos M; Ferakis N; Papatsoris A; Dellis A; Deliveliotis C
J Urol; 2005 Jun; 173(6):1908-11. PubMed ID: 15879773
[TBL] [Abstract][Full Text] [Related]
13. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience.
Kassouf W; Swanson D; Kamat AM; Leibovici D; Siefker-Radtke A; Munsell MF; Grossman HB; Dinney CP
J Urol; 2006 Jun; 175(6):2058-62. PubMed ID: 16697803
[TBL] [Abstract][Full Text] [Related]
14. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Divrik RT; Yildirim U; Zorlu F; Ozen H
J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer.
Jancke G; Damm O; Rosell J; Jahnson S
Scand J Urol Nephrol; 2008; 42(5):417-21. PubMed ID: 18609266
[TBL] [Abstract][Full Text] [Related]
16. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer.
Divrik RT; Sahin A; Altok M; Unlü N; Zorlu F
J Urol; 2007 Sep; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171
[TBL] [Abstract][Full Text] [Related]
17. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression.
Holmang S; Johansson SL
J Urol; 2002 Apr; 167(4):1634-7. PubMed ID: 11912378
[TBL] [Abstract][Full Text] [Related]
18. Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: analysis of patient outcomes.
Boudreaux KJ; Chang SS; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Clark PE
Cancer; 2009 Feb; 115(4):770-5. PubMed ID: 19152431
[TBL] [Abstract][Full Text] [Related]
19. [Modern follow-up strategies for the treatment of patients with superficial bladder carcinoma].
Werner W; Smesny S; Schubert J
Z Arztl Fortbild Qualitatssich; 2000 Aug; 94(6):519-27. PubMed ID: 10996943
[TBL] [Abstract][Full Text] [Related]
20. Fluid intake and the risk of tumor recurrence in patients with superficial bladder cancer.
Donat SM; Bayuga S; Herr HW; Berwick M
J Urol; 2003 Nov; 170(5):1777-80. PubMed ID: 14532774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
